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Background: High recurrence and chemoresistance drive the high mortality in hepatocellular carcinoma
(HCC). Although cancer stem cells are considered to be the source of recurrent and chemoresistant tumors,
they remain poorly defined in HCC. Tonicity-responsive enhancer binding protein (TonEBP) is elevated in
almost all HCC tumors and associated with recurrence and death. We aimed to identify function of TonEBP in
stemness and chemoresistance of liver cancer.
Methods: Tumors obtained from 280 HCC patients were analyzed by immunohistochemical analyses. Stem-
ness and chemoresistance of liver CSCs (LCSCs) were investigated using cell culture. Tumor-initiating activity
was measured by implanting LCSCs into BALB/c nude mice.
Findings: Expression of TonEBP is higher in LCSCs in HCC cell lines and correlated with markers of LCSCs
whose expression is significantly associated with poor prognosis of HCC patients. TonEBP mediates ATM-
mediated activation of NF-kB, which stimulates the promoter of a key stem cell transcription factor SOX2. As
expected, TonEBP is required for the tumorigenesis and self-renewal of LSCSs. Cisplatin induces the recruit-
ment of the ERCC1/XPF dimer to the chromatin in a TonEBP-dependent manner leading to DNA repair and
cisplatin resistance. The cisplatin-induced inflammation in LSCSs is also dependent on the TonEBP-ERCC1/
XPF complex, and leads to enhanced stemness via the ATM-NF-kB-SOX2 pathway. In HCC patients, tumor
expression of ERCC1/XPF predicts recurrence and death in a TonEBP-dependent manner.
Interpretation: TonEBP promotes stemness and cisplatin resistance of HCC via ATM-NF-kB. TonEBP is a key
regulator of LCSCs and a promising therapeutic target for HCC and its recurrence.
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Most cancer patients die not from the primary tumor but from a
reconstituted tumor. The 2nd or 3rd most likely leading cause of can-
cer-associated death is liver cancer, in which hepatocellular carcinoma
(HCC) is the major histological subtype accounting for 7085% of cases
of primary liver cancer [1]. Surgical resection has been considered as a
primary treatment option of liver cancer due to inherent resistance to
chemotherapeutic agents [2]. However, recurrence is nearly 70% even
after complete resection leading to a very high mortality. Despitenumerous efforts, molecular pathways involved in recurrence as well
as chemoresistance of HCC remain poorly understood [2, 3].
Cancer stem cells (CSCs) or tumor-initiating cells, a small subset of
cells within a solid tumor, are considered to be the source of recur-
rent and chemoresistant tumors [4]. Identification of CSCs arises
from the finding that tumor cells are heterogeneous [5, 6]. CSCs dis-
play elevated ability to cope with cellular stresses including resis-
tance to chemotherapeutic agents and highly activated DNA damage
response (DDR) [7]. CD44, CD133, EpCAM, or ALDH are established as
CSC markers for various cancers [8-11]. Expression of these markers
is associated with recurrence and death. Recently, markers for liver
stem cells (LCSCs) have been proposed [12, 13]. However, their func-
tional role in HCC patients are not fully defined and mechanistic basis
for tumor initiation leading to HCC is not known.
The transcription factors NF-kB are highly activated in tumor cells
and CSCs [14] due to DNA damages caused by exposure to
Research in context
Evidence before this study
Hepatocellular carcinoma (HCC) is a common cancer with high
mortality rate due to extremely high recurrence rate and lack of
effective chemotherapeutic agents. We previously showed that
expression of TonEBP in tumors and surrounding areas predicted
recurrence and death, but underlying mechanisms remain unde-
fined. Cancer stem cells (CSCs) are essential in tumor recurrence
due to their tumor-initiating capacity and inherent chemoresist-
ance. Although several surface markers of CSCs have been
reported in HCC, molecular pathways involved are not known.
Added value of this study
Here, we uncover molecular pathways responsible for the
recurrence and chemoresistance in HCC. TonEBP relays local
inflammatory signals to the ATM-NF-kB pathway leading to
SOX2 expression and HCC stemness indicating the importance
of inflammatory microenvironment. Surprisingly, treatment
with cisplatin activates this pathway in a manner dependent on
the interaction between TonEBP and the ERCC1/XPF dimer,
which is involved in a variety of DNA repair processes. High
expression of ERCC1/XPF in tumors predicts recurrence and
death in a manner dependent on the level TonEBP expression
with high levels of significance. Thus, inflammatory signals and
DNA damages caused by cisplatin activate surviving CSCs, both
in a manner dependent on TonEBP.
Implications of all the available evidence
The ATM-NF-kB pathway is an attractive therapeutic target for
HCC and its recurrence. Inhibiting the dual TonEBP actions
might be an effective strategy for this.
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grams transcription network required for the cancer stemness [15]
and the cellular process involved in DDR [16]. Although atax-
iatelangiectasia-mutated (ATM) protein kinase is responsible for
the activation of NF-kB, upstream signals are not known.
Tonicity-responsive enhancer binding protein (TonEBP), also
known as NFAT5, was discovered as a DNA binding transcriptional
enhancer [17]. Numerous studies have revealed, however, that TonEBP
has many other functions [18]. TonEBP is a central component of the
NF-kB enhanceosome assembled on promoters of inflammatory genes
[19]. TonEBP expression is stimulated by inflammation leading to ele-
vated expression of pro-inflammatory genes and chronic inflammatory
diseases [2024]. In addition, TonEBP is recruited to the sites of DNA
damage as an upstream regulator of DDR [25]. The same study also
revealed that TonEBP interactome includes 250 proteins associated
with DDR suggesting that TonEBP has more functions related to DDR.
Of great interest, we recently reported that TonEBP promoted hepato-
cellular carcinogenesis and recurrence [26]. Expression of TonEBP is
higher in tumors compared to surrounding non-tumor regions in
greater than 90% of HCC patients regardless of the etiology of HCC.
Although higher TonEBP expression in tumors predicted recurrence
and death in the HCC patients, underlying mechanism has not been
elucidated. In this study, we discover that TonEBP is a key regulator for
the central signaling pathways in LCSCs: TonEBP is the upstream regu-
lator of ATM in two separate pathways. TonEBP stimulates ATM in
response to inflammatory signals leading to activation of NF-kB, which
in turn enhances stemness and chemoresistance. In the other pathway,
TonEBP recruits the ERCC1/XPF dimer, a prominent DNA repair protein
complex, to the chromatin. The ERCC1/XPF stimulates the ATM-NF-kBaxis in a TonEBP-dependent manner as well as DNA repair in response
to cisplatin treatment. Thus, TonEBP regulates both of the two key
properties of LCSCs self-renewal and chemoresistance.
2. Materials and methods
2.1. Human HCC samples and clinical information
This research was approved by the Institutional Review Board at
the Ulsan University Hospital (UUH 2015-12-018). A total of 280
patients who underwent hepatic resection for HCC from January
2008 to February 2017 at the Ulsan University Hospital, University of
Ulsan, College of Medicine, Ulsan, Korea, were included in the study.
Written consent form was received from each patient. All patients
were HCC treatment-naïve before surgery. The patients were pre-
dominantly males (84.6%) with average age of 56.6 years. The median
follow-up period was 38.0 months (range = 1117 months). Postop-
erative recurrence was observed in 150 cases (53.6%). During postop-
erative follow-up period, metastasis and death were observed in 63
(22.5%) and 92 (32.9%) of cases, respectively. Data were expressed as
mean +/- standard deviation or median (range). For statistical signifi-
cance, Student t-test and chi-squared test were used for comparisons
of variables between groups. The cumulative relapse and survival
rates were evaluated by the KaplanMeier method, and differences
were determined by the log-rank test. A multivariate analysis was
carried out to identify the independent predictor for recurrence,
metastasis and survival using the Cox regression hazard model. All
data were analyzed using the statistical package SPSS for Windows
(version 21.0; SPSS Inc.). In all cases, a two-tailed P-value less than
0.05 was considered statistically significant. Additional protocols and
procedures are described below.
2.2. Tissue array
Human HCC patient tissue samples were collected as previously
described [26]. H&E of each patient was analyzed by histologist, and
hepatic tumor regions of 280 HCC patients in formalin-fixed paraffin-
embedded tissue were marked and extracted for tissue array. Then,
extracted tissues were arranged, molded by using tissue microarray
cassette, and solidified for tissue array analysis. The arrays were proc-
essed simultaneously for immunohistochemistry.
2.3. Oncosphere formation assay
Cells were seeded on ultra-low attachment culture dishes (Corn-
ing) in serum-free medium. DMEM/F12 serum-free medium (Invitro-
gen) contained 2 mM L-glutamine, 1% sodium pyruvate (Invitrogen),
100 mg/ml penicillin G, and 100 U/ml streptomycin supplemented
with 20 ng/ml epithelial growth factor (Invitrogen), 10 ng/ml fibro-
blast growth factor-2 (Invitrogen), N2 (Invitrogen), and B27 (Invitro-
gen). Cells were cultured for one to two weeks.
2.4. Animals
All the methods involving live mice were carried out in accordance
with the approved guidelines. All experimental protocols were approved
by the Institutional Animal Care and Use Committee of the Ulsan
National Institute of Science and Technology (UNISTACUC-12-15-A).
To induce HCC, we administrated a single intraperitoneal injection
of 25 mg/kg diethylnitrosamine (DEN) (N0756; Sigma) to 2-week-old
C57BL/6 mice and euthanised them at 9 months of age [25].
2.5. Xenograft transplantation of CSCs
For subcutaneous injection models, different dilutions (101, 102,
103, or 104) of control and treated cells from oncosphere formation
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6 weeks, with Matrigel Basement Membrane Matrix (BD biosciences)
into two sides of the same nude mouse at the posterior dorsal flank
region (n = 68). Tumor-initiating frequency was calculated by limit-
ing dilution assay according to the protocol available from web
(http://bioinf.wehi.edu.au/software/elda/). The mice were main-
tained under standard conditions according to the institutional
guidelines for animal care.
2.6. Immunohistochemistry (IHC) and histology analysis
Liver tissues were fixed overnight in 4% paraformaldehyde,
embedded in paraffin, and cut into 5 mm sections. Paraffin sections
were deparaffinized and dehydrated. Antigen was retrieved by citrate
and peroxidase or EDTA and peroxidase in appropriate time for each
antigen. Anti-ERCC1 antibodies (CST), anti-XPF antibodies (Abcam),
anti-EpCAM antibodies (Millipore) and anti-CD44 antibodies (Abcam)
were used for IHC using optimized conditions. Signal intensity from
immunohistochemical analyses were measured and sub-grouped
using image software (Fiji-Image J).
2.7. Cell line
Hep3B from American Type Culture Collection (ATCC) was main-
tained in modified Eagle's medium (Hyclone) supplemented with
10% fetal bovine serum (FBS; Thermo) with penicillin-streptomycin
(Hyclone). PLC/PRF/5 and Huh7 cells from ATCC were maintained in
Roswell Park Memorial Institute 1640 supplemented with 2.05 mM
L-glutamine, 25 mM HEPES, 10% FBS, and penicillin-streptomycin.
U2OS cells was maintained in Dulbecco's Modified Eagle Medium
supplemented with 10% FBS with penicillin-streptomycin. Cells were
maintained at 37 °C in incubator with 5% CO2. Cells were transfected
with siRNA (3 nM) using lipofectamine RNAiMAX (Invitrogen) fol-
lowing the manufacturer’s instructions. Control shRNA and TonEBP
shRNA were used for generating lentivirus-mediated knockdown in
HCC cell lines. Positive cells were selected with puromycin for 5 days.
Cell viability was determined by counting the viable cells or mea-
suring the reduction of 3-(4,5-Dimethyl-2-thiazolyl)2,5-diphenyl-
2H-tetrazolium bromide (MTT, Sigma). To examine cell death, cells
were cultured under described conditions in 96-well plates (Corning)
and cell death was examined Caspase-Glo (Promega) assays.
2.8. Quantitative real-time PCR (RT-qPCR)
Total RNA was isolated using the TRIzol reagent (Invitrogen) fol-
lowed by chloroform and ethanol precipitation. cDNA was synthe-
sized by M-MLV reverse transcriptase (Promega) according to the
manufacturer’s instructions. After reverse transcription, Q-PCR was
















CCL2 GGCTGAGACTAACCCAGAAAC GAATGAAGGTGGCTGCTATGAMeasured cycle threshold values were normalized with GAPDH and
they were expressed as fold-over control samples. All RT-qPCR reac-
tions were duplicated.
2.9. Immunoblotting
Cell lysis for protein extraction was performed as previously
described [19, 26]. Briefly, Cells were washed two times with cold PBS
and lysed in RIPA buffer (0.01 M Tris, pH 7.4, 0.15 M NaCl, 0.001 M
EDTA, 0.001 M EGTA, 1% Triton-X 100, 0.002 M PMSF, and protease
inhibitor (Roche). After centrifugation of lysate, supernatant was used
for immunoblot assay. Protein concentration was measured by BCA
system (Pierce). Equal amounts of protein from each sample were sep-
arated by SDS-PAGE and immunoblotted using specific primary anti-
bodies. HRP-conjugated secondary antibodies were used for detection.
The antigen-antibody binding was detected by enhanced chemilumi-
nescence Western blotting detection reagents (GE healthcare life sci-
ences). Anti-SOX2 antibodies (CST); anti-phospho-ATM antibodies
(CST); anti-ATM antibodies (CST); anti-phospho-p65 antibodies (Santa
Cruz); anti-p65 antibodies (CST); anti-phsohpo-STAT3 antibodies
(CST); anti-STAT3 antibodies (CST).
2.10. Flow cytometry and cell sorting
Cells were stained using antibodies according to the manufac-
turer’s instructions. Labeled cells were detected using FACSCalibur
(BD Immunocytometry Systems). For sorting of CD133 and CD90
double positive cells, cocktail PE-conjugated anti-human CD133 (Mil-
tenyi) and FITC-conjugated anti-human CD90 antibodies (Miltenyi)
were incubated with cells. Then cells were sorted with FACS Aria III
(BD Immunocytometry Systems). For sorting of CD133 positive cells,
magnetic-activated cell sorting (MACS) technology based on CD133
(Miltenyi) were performed.
2.11. Oncosphere formation assay
Cells were seeded on ultra-low attachment culture dishes (Corn-
ing) in serum-free medium. DMEM/F12 serum-free medium (Invitro-
gen) contained 2 mM L-glutamine, 1% sodium pyruvate (Invitrogen),
100 mg/ml penicillin G, and 100 U/ml streptomycin supplemented
with 20 ng/ml epithelial growth factor (Invitrogen), 10 ng/ml fibro-
blast growth factor-2 (Invitrogen), N2 (Invitrogen), and B27 (Invitro-
gen). Cells were cultured for one to two weeks. For limiting dilution
assay, different number of cells were plated in 96-well multiwall
plate and the number of wells not forming oncosphere was counted
and stem cell frequency was calculated with limiting dilution assay
according to the protocol available from web (http://bioinf.wehi.edu.
au/software/elda/).
2.12. TCGA analysis
Upper Quantile normalized FPKM (FPKM-UQ) of RNA-seq and
matched clinical information of HCC cohorts was extracted from
metadata of TCGA of Genomics Data Commons portal (https://gdc-
portal.nci.nih.gov). With R studio, the transcript level of TonEBP and
SOX2 was analyzed in HCC patients expressing SOX2 (n = 271). Corre-
lation analysis between TonEBP and SOX2 were generated using R-
derived RNA-seq and plotted with Excel.
2.13. Annexin-V/propidium iodide (PI) double staining assay
Apoptotic cells were determined with an FITC-Annexin V Apopto-
sis Detection Kit (BD Biosciences, San Diego, CA, USA) according to
the manufacturer’s protocol. Briefly, the cells were washed and incu-
bated for 15 min at room temperature in the dark containing FITC-
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etry (BD Biosciences, San Diego, CA, USA).
2.14. Immunofluorescence, microscopy, and image analysis
Cells were plated in LabTek chamber slides (Thermo Fisher Scien-
tific) and incubated before fixation with 4% paraformaldehyde for
20 min at 25 °C before permeabilization (15 min) with PBS containing
0.2% Triton X-100. Antibody incubation was performed as recom-
mended, followed by mounting. Edu (Thermo Fisher Scientific) label-
ing is performed as manufacturer’s instructions (Click-iTTM EdU Alexa
FluorTM 594 Imaging Kit).
2.15. Nuclear and cytoplasmic fractionation
Cells were harvested by using scrapper and centrifuged. The cell
pellet was washed by suspension with PBS. The cell nucleus and cyto-
plasm were separated by using Nuclear and Cytoplasmic extraction
kit (Pierce) according to manufacturer’s instruction.
2.16. Tight chromatin-bound fractionation
Tight chromatin-bound fraction was isolated as previously
described [27]. In brief, cell pellets were sequentially washed in CEBN
buffer (10 mM HEPES [pH 7.8], 10 mM KCl, 1.5 mM MgCl2, 0.34 M
sucrose, 10% glycerol, 0.2% NP-40, 1X protease inhibitor cocktail
(Invitrogen), and 1X phosphatase Inhibitor cocktail), CEB buffer
(CEBN buffer without NP-40), soluble nuclear buffer (3 mM EDTA,
0.2 mM EGTA, protease and phosphatase inhibitor), and salt buffers
with 0.45 M NaCl buffer.
2.17. Promoter and reporter assay
Human SOX2 promoter-containing plasmids were obtained from
Addgene (pGL3-Sox2, Plasmid #101761) were inserted into pGL3
(Promega). kB binding sites in SOX2 promoter was mutated using
cloned SOX2 promoter with primers and indicated as DkB. Cells were
transfected luciferase plasmid. The Renilla luciferase reporter plas-
mid (pRL-TK, Promega) was used as a control for transfection effi-
ciency. Luciferase activity after 6 h of stimulation was measured
using the Dual-Luciferase Assay System (Promega) according to the
manufacturer’s instructions. Luciferase activity was normalized by
activity of renilla luciferase.
2.18. Immunoprecipitation and chromatin immunoprecipitation (ChIP)
For preparation of lysates for IP, cells were washed three times
with ice-cold PBS and lysed in RIPA buffer as described previously
[18]. An appropriate antibody was added to lysates and incubated
overnight at 4 °C, followed by incubation with Protein A/G Sepharose
beads (GE Healthcare Sciences). After extensive washing with RIPA
lysis buffer, complexes were eluted and analyzed by immunoblotting.
Anti-ERCC1 antibodies (CST); anti-XPF antibodies (Abcam); anti-Myc
antibodies (CST). ChIP was performed as previous studies [25]. In
brief, cells were crosslinked with 1% formaldehyde followed by addi-
tion of 125 mM glycine. After washing, cells were sonicated and
immunoprecipitated with anti-IgG, and anti-p65 (CST) antibodies at
4 °C overnight. After elution and reverse crosslinking the antibody/
DNA complexes, DNA was purified by DNA purification kit (Qiagen)
and analyzed by q-PCR using primer pairs covering specific region of
the SOX2 promoter in duplicates.
2.19. TonEBP interaction analysis
We analyzed the candidate of TonEBP-interacting protein from the
interactome data of previous report [25]. To isolate TonEBP-interactingproteins, HEK293 cells were transfected with the pcDNA5/FRT empty
vector or pcDNA5/FRT-TonEBP-Flag plasmid. The cells were lysed in
1 ml of RIPA buffer supplemented with a protease inhibitor cocktail
and 0.5 mM phenylmethylsulfonyl fluoride at 24 h post-transfection.
Cell extracts were recovered by centrifugation at 12,000 rpm (Eppen-
dorf, 5424R) for 15 min at 4 °C. The cleared supernatants were col-
lected, and the cell lysates were mixed with 50 ml (50% slurry) of anti-
Flag M2 resin (Sigma-Aldrich) and incubated at 4 °C for four hours.
After centrifugation at 2500 rpm (Eppendorf, 5424R) for five minutes,
the supernatants were discarded, and the collected resin samples were
washed in 1 ml of RIPA lysis buffer five times. Flag-tagged TonEBP and
bound proteins were eluted with excessive amounts of the 3 £ Flag
peptide (Sigma-Aldrich). Eluted proteins were subjected to immuno-
blotting. The molecular identities of the eluted proteins were deter-
mined bymass spectrometry.
2.20. Quantification and statistical analysis
Data are presented as means + S.D or means + S.E.M. Statistical sig-
nificance (p < 0.05) was estimated by an unpaired ttest for compar-
isons between two conditions. Two-way ANOVA was performed for
multiple comparison. All statistical analyses were performed using
Student’s t-test. n = number of experimental replicates.
3. Results
3.1. TonEBP promotes self-renewal of liver cancer stem cells
The motivation of this study was to understand how hepatic
TonEBP expression leads to recurrence of HCC [26]. In order to gain a
clue on molecular pathways involved in the recurrence, we decided
to examine known markers of LCSCs (CD44, EpCAM, CD133, CD13,
CD90, c-kit, and CK-19) in the cohort of HCC patients we had studied
[26]. We found that high expression of EpCAM and CD44 was
observed in 102 and 94 patients, respectively, out of 280 patients
(Supplementary Fig. 1a,b). We did not pursue other markers (CD133,
CD13, CD90, c-kit, and CK-19) because their expression was limited
in our cohort, i.e., expression was detected in less than 10% of cases,
making it difficult for meaningful analysis. Interestingly, the expres-
sion of EpCAM and CD44 correlated with each other with very high
significance (Supplementary Fig. 1c and d). Kaplan-Meier analyses
revealed that high expression of EpCAM and CD44 each correlated
significantly with recurrence and death (Fig. 1a,b). These data provide
evidence that LSCSs are involved in the recurrence of HCC in our
cohort providing a basis for us to pursue cancer stem cells.
Our previous study shows that expression of TonEBP is higher in
tumors compared to adjacent non-tumor in HCC patients regardless
of etiology [26]. Since expression of TonEBP in the tumor is signifi-
cantly associated with recurrence [26], we set out to explore the role
of TonEBP in LCSCs. LCSCs within the HCC cell lines in culture were
enriched by oncosphere culture (Fig. 1c) or by selecting for surface
markers CD90 and CD133 (Fig. 1d) [2729]. Expression of TonEBP
was higher in the oncospheres compared to non-sphere; likewise,
CD90+CD133+ cells exhibited higher expression of TonEBP compared
to their counterpart CD90CD133 cells. In addition, expression of
TonEBP showed weak but significant correlation with both EpCAM
and CD44 in the tissue of microarrays of HCC patients (Fig. 1e, f). Fur-
thermore, expression of cancer stem cell-related genes SOX2, Oct4,
and Nanog was reduced in TonEBP haplodeficient animals in the
DEN-induced HCC model [26] (Supplementary Fig. 1e). These obser-
vations suggest that TonEBP plays an important role in LCSCs.
Given the association of TonEBP and LCSCs, we directly investi-
gated the role of TonEBP in LCSCs. Lentiviral knockdown of TonEBP
significantly reduced oncosphere formation (Fig. 1g), stem cell fre-
quency (Supplementary Fig. 1f), and ALDH activity (Fig. 1h), while
overexpression of TonEBP enhanced oncosphere formation
Fig. 1. TonEBP is required for the self-renewal of cancer stem cells. (a,b) KaplanMeier plot of postoperative HCC recurrence and HCC related death in two groups of patients based
on immunohistochemical signals in tissue microarrays prepared from 280 patients with HCC. (a) EpCAMlow (n = 178) versus EpCAMhigh (n = 102) and (b) CD44low (n = 186) versus
CD44high (n = 94). (c) Huh 7 and PLC/PRF/5 cells were cultured for oncosphere formation. Cells in non-sphere and spheres were immunoblotted for TonEBP and Hsc70. (d)
CD90CD133 and CD90+CD133+ cells were obtained from PLC/PRF/5 (PLC), Huh7, and Hep3B cells. TonEBP mRNA was measured by RT-qPCR. Mean + SD. *p < 0.05. (e,f) Relative
TonEBP versus (e) EpCAM or (f) CD44 abundance in tumors from the 280 patients with HCC. (g) TonEBP expression was stably reduced using TonEBP targeting lentivirus (shTonEBP)
in PLC/PRF/5 cells, or not (shCon: control vector). Representative images from oncosphere formation assay (left). Percentage of sphere cells was obtained (right). Mean + SD. *p <
0.05 (h) CD90+CD133+ cells were isolated from the shTonEBP and shCon cells. ALDH activity was measured in cell lysates. Mean + SD, *p < 0.05. (i) RT-qPCR analyses of EMT genes
and stem cell transcription factor (TF) genes in the spheres. Mean + SD. *p < 0.05. (j) The shCon (-) and shTonEBP cells (+) described above were transfected with an expression plas-
mid containing TonEBP, TonEBP-DRHD, Yc1, or Yc1-DRHD as indicated. Cells were cultured for oncosphere formation and representative images are shown (left). Percentages of
sphere cells as Mean + SD (right). *p < 0.05. (k,l) Tumor initiation was measured from (k) Hep3B or (l) PLC/PRF/5 cells as described in Results and expressed as tumor initiating%
(graph at left). From these data, tumorigenic cell frequency was calculated with limiting dilution assays according to the protocol available from web (http://bioinf.wehi.edu.au/soft
ware/elda/) and presented on the right as a table. Images of tumors formed are shown for PLC/PRF/5 cells.
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genes related to the cancer stemness and LCSCs markers was
observed in the TonEBP-deficient oncosphere population (Fig. 1i and
Supplementary Fig. 1i) while the opposite was observed in the
TonEBP-overexpressed oncospheres (Supplementary Fig. 1j). These
results demonstrate that TonEBP drives the self-renewal of LCSCs.
Next, we asked which domain of TonEBP is responsible for the onco-
sphere formation. Rel-homology domain (RHD) consists of about 270
amino acid residues near the N-terminus of TonEBP. RHD is responsi-
ble for DNA binding [17], and interactions with NF-kB and proteins
involved in DDR [19, 25]. In order to define the role of RHD in onco-
sphere formation, various constructs were transfected to the cells
whose TonEBP was stably knocked down: TonEBP, TonEBP-DRHD
(RHD deleted), Yc1 (N-terminal one third of TonEBP including RHD),
and Yc1-DRHD. As shown in Fig. 1j, TonEBP and Yc1 restored the
oncosphere formation while TonEBP-DRHD and Yc1-DRHD did not
indicating that RHD is essential in the self-renewal of LCSCs. These
results suggest that protein-protein interactions are critical for the
TonEBP’s ability to drive the self-renewal of LCSCs.
Ability to form reconstituted tumor is the key feature of CSCs. We
next assessed the function of TonEBP in tumor initiation. The onco-
spheres from the TonEBP knocked down or control cells described
above were trypsin digested to form single cell suspensions. 104, 103,
102 or 101 cells were subcutaneously injected into BALB/c nude mice
and tumors were examined 3 months later. Both in Hep3B (Fig. 1k)
and PLC/PRF/5 cells (Fig. 1l) tumor initiating capacity and tumor initi-
ating frequency were dramatically reduced in the TonEBP-deficient
cells demonstrating that TonEBP is required for reconstituted tumor
formation. Taken together with the roles of TonEBP in the expression
of markers for LCSCs and self-renewal of LCSCs described above,
these results demonstrate that TonEBP promotes self-renewal of
LCSCs.
3.2. TonEBP promotes cancer stemness via ATM-NF-kB-SOX2
Inflammation has been recognized as a major contributing factor
for recurrent tumors [30]. In fact, inflamed tumor microenvironment
is critical for self-renewal of CSCs [14, 30]. We previously observed
that hepatic TonEBP deficiency mitigated inflammation and liver
injury [26]. To explore the hypothesis that TonEBP promotes cancer
stemness in response to inflamed environment, we examined effects
of TNFa on expression of stem cells transcription factors in HCC cells.
While mRNA for Oct4, Nanog, KLF4 and Nestin was elevated in a
TonEBP-dependent manner, their increase was preceded by that of
SOX2 mRNA which peaked at 6 h of treatment (Fig. 2a). As expected,
there is a clear increase in the protein level of SOX2, also in a
TonEBP-dependent manner (Supplementary Fig. 2a). Thus, TonEBP
has prominent influence on SOX2 expression in LCSCs.
We next investigated how TonEBP regulates the expression of
SOX2. Since SOX2 expression in CSCs is driven by NF-kB [31, 32], we
examined NF-kB and its upstream regulator ATM [33]. As expected,
phosphorylation (activation) of ATM and p65 was stimulated by
TNFa (Fig. 2b) in RHD- dependent manner (Supplementary Fig. 2b).
Since there is no evidence of direct interaction between TonEBP and
ATM, we conclude that TonEBP indirectly activates ATM and subse-
quent signaling. Interestingly, the activation of ATM and p65 was
TonEBP-dependent as it was blocked by TonEBP knockdown. ATM
inhibitor (ATMi, KU55933) blocked not only the phosphorylation of
p65 (Fig. 2c) but also expression of SOX2 and Oct4 mRNA (Fig. 2d)
and ALDH activity (Fig. 2e). Our interpretation is that suppression of
SOX2 to leads to overall reduction in stemness. Next, we examined
the SOX2 promoter. The promoter was stimulated by TNFa in a
TonEBP-dependent manner, while it was inhibited by ATMi and BAY
117082 (BAY, an inhibitor of IKK which blocks the activation of NF-
kB) (Fig. 2f). The effects of BAY were supported by the observation
that the stimulation of the promoter by TNFa was dependent on thepresence of NF-kB binding site (Supplementary Fig. 2c). ChIP analyses
revealed that binding of the p65 subunit of NF-kB to the SOX2 pro-
moter was also stimulated by TNFa in a TonEBP-dependent (Fig. 2g)
and ATM-dependent manner (Fig. 2h). Furthermore, TonEBP-medi-
ated stimulation of SOX2 expression and cancer stemness was depen-
dent on RHD (Supplementary Fig. 2df), and ATM is required for the
function of TonEBP in stimulation of SOX2 expression (Supplemen-
tary Fig. 2g). These data demonstrate that TNFa stimulates the SOX2
promoter via the ATM-NF-kB pathway.
We asked prognostic association of SOX2. When the 280 HCC
patients were stratified into two groups based on SOX2 immunohis-
tochemical signals (Supplementary Fig. 2h), higher expression of
SOX2 displayed strong association with HCC recurrence, HCC metas-
tasis, and HCC related death (Fig. 2i). Furthermore, the SOX2 expres-
sion correlated with TonEBP expression with high significance in our
cohort of HCC patients (Supplementary Fig. 2i, j) and in analysis of
the RNA-seq data set from TCGA (Supplementary Fig. 2k) confirming
the role of TonEBP in driving SOX2 expression. Taken together, these
results demonstrate that TonEBP promotes HCC cancer stemness by
driving SOX2 expression.
3.3. TonEBP promotes cisplatin resistance and DDR in LCSCs
CSCs contribute to the resistance of cancers to chemotherapy
[46]. This is due, at least in part, to their elevated DDR [4]. Since the
data discussed above show that TonEBP promotes self-renewal of
LCSCs, we next asked whether TonEBP is involved in the chemoresist-
ance. We used cisplatin which damages DNA mainly by forming vari-
ous DNA crosslinks and induces cell death [34]. We first examined
cell survival in response to cisplatin treatment (Fig. 3a). Cisplatin
killed PCL/PRF/5 cells in a dose-dependent manner. Interestingly, the
cell death increased after TonEBP knockdown leading to a decrease
in LD50 indicating that TonEBP was protective. On the other hand,
the cell death was blocked by TNFa. The protective effect of TNFa is
likely due to increased stemness as discussed above.
Since TonEBP is protective from cisplatin-induced cell death inde-
pendent of TNFa (Fig. 3a), we examined this more closely. The effect
of RNAi-mediated transient knockdown of TonEBP was observed in
the three HCC cell lines based on both live cell counting and MTT
assay (Fig. 3b, Supplementary Fig. 3a). As expected, activity of cas-
pases 3/7 (Fig. 3c and Supplementary Fig. 3b) and Annexin V-positive
(apoptotic) cells (Supplementary Fig. 3c) were elevated by cisplatin
treatment also in a TonEBP-dependent manner. Reversely, TonEBP
overexpression was protective in 3 different HCC cell lines
(Supplementary Fig. 3d). Cell populations enriched for LCSCs by
selecting for CD133 (CD133+ cells) were less sensitive to cisplatin
compared to CD133 (Fig. 3d, Supplementary Fig. 3e). Of note,
TonEBP-dependent cisplatin resistance was greater in the CD133+
cells consistent with elevated DDR in LCSCs. Since TonEBP interacts
with many proteins in DDR [25], it is likely that the TonEBP-mediated
cisplatin resistance is due to DDR.
Cisplatin targets DNA by forming DNA adducts, both intrastrand
and interstrand crosslinks [34]. We asked which crosslink was
responsible for the TonEBP-dependent cell death. UV was used to
produce intrastrand crosslinks and mitomycin C (MMC) to produce
interstrand crosslinks. TonEBP deficiency increased cell death in
response to both agents (Fig. 3e, f and Supplementary Fig. 3f, g) indi-
cating that TonEBP protects from both DNA adducts produced by cis-
platin. Next we examined DNA damages and DDR in response to
cisplatin treatment. Cisplatin treatment resulted in activation (phos-
phorylation) of both checkpoint kinase 1 (Chk1) and 2 (Chk2)
(Fig. 3g) consistent with single-strand and double-strand DNA breaks.
As expected, abundant DNA repair activity was detected by EdU (5-
ethynyl-20-deoxyuridine) labeling (Fig. 3h). Cisplatin-induced DNA
damages measured by alkaline comet assay (Fig. 3i) and H2AX phos-
phorylation (Fig. 3j, k) were elevated in the TonEBP-deficient cells.
Fig. 2. TonEBP promotes cancer stemness via ATM-NF-kB-SOX2. (a) Stem cell transcription factors were analyzed in shCon and shTonEBP PLC/PRF/5 cells after treatment with TNFa
(10 ng/ml) for up to 24 h, as indicated, using RT-qPCR. Mean + SD. *p < 0.05. (b) Immunoblot analyses of p-ATM, ATM, p-p65, p65, p-STAT, STAT3 and TonEBP after 2 h treatment
with TNFa or vehicle (Veh). (c) Cells were pretreated with Veh or ATMi followed by a 24 h treatment with TNFa. mRNA of SOX2 and Oct4 were measured. Mean + SD. *p < 0.05. (d)
PLC/PRF/5 cells were transfected with pGL3 (-, bottom) or SOX2 promoter reporter in pGL3 (+). Pretreatment with ATMi or BAY followed by treatment with TNFa (6 h) were per-
formed as indicated. Luciferase activity is shown in mean + SD. *p < 0.05. (e) CD90+CD133+ cells were treated with ATMi or BAY (5 mM of BAY 117082) for 24 h. ALDH activity in
mean + SD. *p < 0.05. (f) PLC/PRF/5 cells were transfected with pGL3 (-, bottom) or SOX2 promoter reporter in pGL3 (+). Pretreatment with ATMi or BAY followed by treatment with
TNFa (6 h) were performed as indicated. Luciferase activity is shown in mean + SD. *p < 0.05. (g) ChIP was performed on cells treated with Veh or TNFa (2 h) using anti-p65 IgG
(a-p65) or normal IgG (IgG). DNA fragments containing the kB site in the SOX2 promoter was quantified using qPCR. Mean + SD. *p < 0.05. (h) ChIP was performed using anti-p65
IgG on cells pretreated with Veh or ATMi followed by a 2 h treatment with Veh or TNFa. Mean + SD. *p < 0.05. (i) Kaplan-Meier plot of postoperative recurrence, metastasis, and
HCC related death in two groups of patients: SOX2low (n = 137) vs. SOX2high (n = 143).
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nals and DNA repair activity despite elevated DNA damages provid-
ing strong evidence that TonEBP mediates DDR as well as resistance
in response to cisplatin treatment.
3.4. TonEBP interacts with ERCC1/XPF via RHD domain
In order to address molecular basis of the TonEBP-mediated DNA
repair activity described above, we examined the 250 DDR proteins
that interacted with TonEBP [25]. Becuase nucleotide exchange repair
(NER) is a major repair pathway for DNA damage caused by cisplatin
[33], we looked for proteins involved in NER and found three proteins- MMS19, ERCC1 and XPF. We became interested in ERCC1 and XPF
because the ERCC1/XPF heterodimer repairs intrastrand and intra-
strand crosslinks caused by cisplatin [34]. Expression of ERCC1/XPF is
associated with cisplatin resistance and poor outcome after anti-can-
cer therapy in a variety of cancer types [35, 36]. However, little is
known about the role of ERCC1/XPF in liver cancer.
We confirmed that ERCC1 and XPF were co-immunoprecipitated
by TonEBP from cell lysates (Fig. 4a). In addition, the interactions
were stimulated by UV or cisplatin treatment without changes in
their expression levels. The interactions and their stimulation by UV
or cisplatin were also observed in chromatin fractions (Fig. 4b). The
cisplatin-responsive chromatin binding of ERCC1/XPF was reduced in
Fig. 3. TonEBP is required for cisplatin resistance and DNA damage response. (a) PLC/PRF/5 cells transfected with indicated shRNA were treated with TNFa or Veh in combination
with various concentrations of cisplatin for 48 h. Cell viability was analyzed by MTT assay (left) and LC50 values were calculated (right). Mean + SD. *p < 0.05. (b) HCC cell lines
were transfected with siRNA indicated, followed by treatment with cisplatin (5 mM) or vehicle (dimethylformaldehyde 0.025%) for 48 h before counting viable cells. (c) Activity of
caspase 3 and 7 (3/7) was measured from siRNA transfected PLC/PRF/5 cells after a 48 h treatment with cisplatin. (d) CD133+ and CD133 cells were isolated from siRNA transfected
cells. Viable cells were counted after incubation with cisplatin (Cis) or Veh for 48 h. Mean + SD, two-way ANOVA, *p < 0.05. (e) siRNA transfected cells were treated with various
doses of UV as indicated. Viable cells were counted 48 h later. (f) Cells were treated with Veh or 5 mM MMC for 48 h and viable cells were counted. (g) Nuclear extracts from cells
treated for 4 h with Veh or Cisplatin were immunoblotted. (h) Representative images of EdU incorporation in PLC/PRF/5 cells after a 12 h treatment with cisplatin (left). Fluorescence
intensity of EdU per cell is shown on the right. (i) CD133+ cells were isolated from siRNA transfected cells and then treated with cisplatin. Alkaline comet assay was performed and
representative images are shown (left).% of intensity in tail is shown (right). (j,k) p-gH2AX was detected in the siRNA transfected CD133+ cells which had been treated with cisplatin
using (j) immunoblotting and (k) immunohistochemistry.
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proteins; XPA and XPD (Fig. 4c, Supplementary Fig. 4a). mRNA levels
for the genes encoding these proteins were not affected by TonEBP
(Supplementary Fig. 4b) indicating that the TonEBP-mediated DNA
repair activity was independent of transcription regulation. As
expected, TonEBP-mediated chemoresistance was blocked by XPF
knockdown (Fig. 4d) demonstrating that ERCC1/XPF mediates the
TonEBP-dependent cisplatin resistance.
Since the interaction between TonEBP and ERCC1/XPF was con-
firmed by co-localization (Supplementary Fig. 4c), we performed co-
immunoprecipitation experiments to characterize the interaction in
more detail. Overexpressed TonEBP and ERCC1 or XPF were mutually
pulled down by each other (Supplementary Fig. 4d). TonEBP interacts
with other proteins such as NF-kB, YY1, SHPRH and USP1 via the rel-
homology domain (RHD) [19, 25, 26]. We asked whether TonEBP
interaction with ERCC1/XPF was also mediated by RHD. Deletion of
RHD abolished the interaction of TonEBP with ERCC1/XPF (Fig. 4e
and Supplementary Fig. 4e), and TonEBP’s ability to prevent cell
death from cisplatin treatment (Fig. 4f). These data show that TonEBPforms a complex with ERCC1/XPF to promote DNA repair and resis-
tance to cisplatin.3.5. TonEBP-ERCC1/XPF promotes DNA damage-induced ATM/
inflammation activation
Cisplatin treatment induces inflammation in tumors and the kid-
ney [37, 38]. Since TonEBP activates ATM-NF-kB leading to inflamma-
tion and also recruits ERCC1/XPF in response to cisplatin, we asked
whether ERCC1/XPF activated ATM. We found that cisplatin stimu-
lated ATM and NF-kB, and this stimulation was reduced in TonEBP-
deficient cells (Supplementary Fig. 5a). In addition, TonEBP-depen-
dent cisplatin resistance in cell viability was obliterated by treatment
with inhibitors of ATM and NF-kB (Supplementary Fig. 5b). Reversely,
overexpression of TonEBP potentiated the cisplatin-induced phos-
phorylation of ATM and NF-kB (Fig. 5a). These data demonstrate that
cisplatin activate the ATM-NF-kB pathway in a TonEBP-dependent
manner.
Fig. 4. TonEBP interacts with ERCC1/XPF through RHD. (a) PLC/PRF/5 cell lysates were prepared 2 h after treatment without (-) or with UV (+, 150 J/m2) (upper panel) or after a 4 h
treatment with vehicle (-) or cisplatin (+, 5 mM). Immunoprecipitation was performed using normal rabbit serum (Ser) or anti-TonEBP serum (TonEBP). Immunoprecipitates (left)
and cell lysates (right) were immunoblotted. (b) Chromatin fractions were prepared and analyzed after cells were treated as above. (c) Chromatin fractions were prepared from
siRNA transfected PLC/PRF/5 cells after a 4 h treatment with Veh or cisplatin. Immunoblotting was performed for proteins indicated. H3, Histone H3 (a marker for nuclear protein).
(d) PLC/PRF/5 cells were transfected with pcDNA (-) or pcDNA-TonEBP followed by transfection with siRNA indicated. The double transfected cells were treated for 48 h with cis-
platin or vehicle (-). Viable cells were measured by MTT assay. Mean + SD. *p < 0.05. (e) Lysates of HEK293 cells transfected with various combinations of expression vectors as indi-
cated were immunoprecipitated with anti-Myc antibodies, followed by immunoblotting. (f) PLC/PRF/5 cells were transfected with scr or TonEBP siRNA followed by a second
transfection with empty expression vector (pcDNA) or expression vector for TonEBP or TonEBP DRHD as indicated. Cell viability was measured after a 48 h treatment with cisplatin.
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reduced the expression of ERCC1 (Fig. 5a), as reported previously
[39]. Deficiency of ERCC1/XPF was associated with blockade of cis-
platin-induced activation of ATM and NF-kB. While this activation
was greater when TonEBP was overexpressed, it was blocked by XPF
knockdown consistent with the role of TonEBP-ERCC1/XPF. As
expected, cisplatin-stimulated expression of pro-inflammatory cyto-
kine genes was blocked by knockdown of TonEBP or XPF to the same
degrees (Supplementary Fig. 5c), potentiating that they were in the
same pathway. Essentially the same observations were observed by
treatment with UV (Supplementary Fig. 5d, e) and MMC (Supplemen-
tary Fig. 5f, g) indicating that both intrastrand and interstrand cross-
links were associated with the TonEBP-ERCC1/XPF pathway.
Reversely, overexpression of TonEBP stimulated the expression of
pro-inflammatory genes in association with XPF (Fig. 5b); both were
blocked by knockdown of ERCC1/XPF. And TonEBP-mediated activa-
tion of cisplatin-responsive NF-kB activation was dependent on XPF
(Fig. 5c). Finally, we found that ATMi blocked cisplatin-induced acti-
vation of p65 (Supplementary Fig. 5h) and expression of pro-inflam-
matory genes (Supplementary Fig. 5i) confirming the role of ATM in
the activation of NF-kB. Taken together, these results show that DNA
crosslinks produced by cisplatin induce inflammation by activation of
the ATM-NF-kB pathway via the TonEBP-ERCC1/XPF complex
3.6. TonEBP-ERCC1/XPF promotes cancer stemness
Since TonEBP-ERCC1/XPF activated the ATM-NF-kB pathway, we
asked whether TonEBP-ERCC1/XPF promoted the expression of SOX2
and cancer stemness. In addition, RHD, a responsible region of
TonEBP to interact with ERCC1/XPF, is a mediator of TonEBP-depen-
dent regulation of HCC stemness. We observed that cisplatin stimu-
lated the expression of SOX2 and other stemness transcription
factors (Fig. 5d) and elevated ALDH activity (Fig. 5e) indicating pro-
motion of cancer stemness. Only the stimulation of SOX2 expression
displayed clear dependence on XPF and TonEBP when cells are
shortly exposed to cisplatin (Fig. 5d) consistent with a direct role ofTonEBP-ERCC1/XPF. The cisplatin-induced SOX2 expression was sen-
sitive to ATM inhibitor and NF-kB inhibitor, as expected (Fig. 5f).
Interestingly, LCSCs stemness measure by oncosphere formation
was also dependent on TonEBP and ERCC1/XPF in the absence of cis-
platin (Fig. 5g). Under this condition, ERCC1/XPF association with the
chromatin was still dependent on TonEBP (Supplementary Fig. 6a)
and oncosphere formation was dependent on ERCC and XPF (Supple-
mentary Fig. 6b). These observations are likely due to inherent activ-
ity of ERCC1/XPF in CSCs due to high level of DNA damages [7]. Thus,
TonEBP-ERCC1/XPF appears to be an essential feature of LCSCs
responsible for driving cancer stemness even in the absence of exter-
nal DNA damaging agents.
3.7. Tumor ERCC1 and XPF predicts poor prognosis of HCC in TonEBP
dependent manner
In order to examine the role of ERCC1/XPF in the recurrence of
HCC, we examined hepatic tissues obtained from 280 HCC patients
(Supplementary Table 1). ERCC1 stained negative in 89 patients while
positive in 191 patients, of which 95 showed low signal and 96
showed high signal (Fig. 6a, Supplementary Table 2). Likewise, XPF
stained negative in 103 patients while positive in 173 patients, of
which 89 showed low signal and 88 showed high signal (Fig. 6a, Sup-
plementary Table 2). For further analyses described below, those
patients who displayed no immunohistochemical signal were
excluded from analyses. Univariate analysis of the two layers of
patients in each of ERCC1 and XPF showed highly significant associa-
tion with recurrence, metastasis and death (Supplementary Table 2).
Kaplan-Meier plot confirmed the higher recurrence, metastasis, and
death in patients with high tumor ERCC1/XPF expression (Fig. 6bd).
This was analyzed further using multivariate analyses (Supplemen-
tary Table 3). As for recurrence, tumor size, microvascular invasion
along with tumor ERCC1/XPF expression displayed strong associa-
tion. Tumor size and tumor ERCC1/XPF expression showed a robust
association with metastasis. Finally, microvascular invasion and
tumor ERCC1/XPF were significantly associated with survival. Taken
Fig. 5. TonEBP-ERCC1/XPF mediates cisplatin-induced inflammation and stemness. (a) Cells were transfected with pcDNA (-) or pcDNA-TonEBP (+) followed by transfection with
siRNA as indicated. The cells were then treated with cisplatin or vehicle (-) for 48 h before immunoblotting. (b) Cells were transfected with pcDNA or pcDNA-TonEBP followed by
transfection with siRNA as indicated. Inflammatory genes were analyzed by RT-qPCR after a 6 h treatment with vehicle (-) or cisplatin. Mean + SD, two-way ANOVA, *p < 0.05. (c)
siRNA transfected cells were transfected again with an NF-kB reporter construct. Luciferase activity was measured after a 2 h treatment with vehicle (-) or cisplatin. (d) Cells were
transfected with various combinations of siRNA and pcDNA-TonEBP as indicated. Stem cell transcription factors were analyzed by RT-qPCR after a 6 h treatment with vehicle (-) or
cisplatin. Mean + SD, two-way ANOVA, *p < 0.05. (e) ALDH activity was analyzed after a 24 h treatment of vehicle or cisplatin in CD133+ cells. (f) siRNA transfected cells were pre-
treated for 1 h with Veh, ATMi, or BAY followed by a 6 h treatment with vehicle or cisplatin. Expression of TonEBP and SOX2 was analyzed by RT-qPCR. (g) Cells were transfected
with pcDNA (-) or pcDNA-TonEBP followed by a second transfection with scr siRNA (-) or ERCC1 siRNA + XPF siRNA as indicated. Cells were cultured for oncosphere formation and
representative images are shown (left). Percentages of sphere cells in Mean + SD (right). *p < 0.05.
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ERCC1/XPF expression predicts post-operative recurrence, metasta-
sis, and death in HCC patients.
We next examined TonEBP dependency in the ERCC1/XPF-medi-
ated poor post-operative prognosis. For this, we analyzed 156
patients who displayed high signal for both ERCC1 and XPF. And
patients were further stratified into 2 groups by previously reported
TonEBP signals [26]. Of these patients, 41 showed low TonEBP signalwhile 115 showed high TonEBP signals (Supplementary Table 4). The
high TonEBP group displayed higher recurrence, metastasis and
death in univariate analysis (Supplementary Table 4) and Kaplan-
Meier analysis (Fig. 6e) confirming the role of TonEBP-ERCC1/XPF in
poor prognosis as predicted by its role in cancer stemness described
above. These results provide strong evidence that ERCC1/XPF medi-
ates the TonEBP’s actions on poor post-operative outcome in HCC
patients.
Fig. 6. Tumor ERCC1/XPF predicts poor post-operative prognosis in HCC patients in TonEBP-dependent manner. (a) Representative immunohistochemical images of ERCC1 and XPF
in hepatic tumors from patients with HCC. (bd) KaplanMeier plot of postoperative (b) recurrence, (c) metastasis, and (d) HCC-related death in four groups of patients: ERCC1low
(n = 95) vs. ERCC1high (n = 96) and XPFlow (n = 89) vs. XPFhigh (n = 88). (e) Kaplan-Meier plot of postoperative recurrence, metastasis, death and HCC related death in two groups of
patients: ERCC1high;XPFhigh;TonEBPlow (n = 41) vs. ERCC1high;XPFhigh;TonEBPhigh (n = 115). (f) Proposed model for the regulation of liver cancer stemness and chemoresistance by
TonEBP.
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The motivation of this study is to understand how high TonEBP in
tumors leads to recurrence after resection of the tumors in HCC
patients [26]. In a cohort of 280 HCC patients, we find clear evidence
that EpCAM and CD44 are markers for LCSCs related to recurrence.
Interestingly, expression of EpCAM and CD44 in HCC tumors corre-
lates with that of TonEBP suggesting TonEBP’s role. Indeed, studies
using HCC cell lines has shown that TonEBP is involved in self-
renewal and tumor-initiating activity of LCSCs via two separate path-
ways as summarized in Fig. 6f. TonEBP relays inflammatory signals toATM leading to SOX2 expression and self-renewal of LCSCs. In the
other pathway, TonEBP recruits the ERCC1/XPF dimer to the chroma-
tin using protein-protein interactions. High level of DNA damages
(both intrastrand and interstrand DNA crosslinks) due to intracellular
stress within LCSCs activates ATM via the TonEBP-ERCC1/XPF com-
plex on the chromatin. This pathway is responsible for the inflamma-
tion and cancer stemness induced by cisplatin treatment. Consistent
with this model, tumor expression of ERCC1 and XPF predicts recur-
rence with extremely high significance in TonEBP-dependent man-
ner. The TonEBP actions described here provide molecular basis for
two common observations. One is that inflammatory
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platin-induced inflammatory microenvironment contributes CSCs to
form chemoresistant and reconstituted tumor [40, 41]. The TonEBP’s
role in cisplatin resistance requires additional evidence using TonEBP
overexpressing tumors in animals in addition to the TonEBP knock-
down tumors described here. The TonEBP-dependence of the associa-
tion of ERCC1 and XPF with recurrence in HCC patients (Fig. 6e)
provides solid grounds for future investigation into underlying
molecular pathways.
TonEBP is a pleiotropic transcriptional regulator  DNA binding
transcriptional enhancer [17], transcriptional cofactor [19, 26] and
epigenetic suppressor [24]. A recent study has uncovered non-tran-
scriptional functions of TonEBP where TonEBP recognizes bulky DNA
adducts and regulate ubiquitination of proliferating cell nuclear anti-
gen through dynamic interactions with E3 ubiquitin ligase SHPRH
and deubiquitinase USP1 [25]. This study adds more functions of
TonEBP related to intracellular signal transduction and DDR as dis-
cussed above. Since the TonEBP interactome includes more than 450
proteins [25], other functions of TonEBP mediated by protein-protein
interactions are likely to be uncovered in the future.
Although markers for LCSCs have been proposed based on clinical
studies [12, 13], cellular pathways involved have not been defined.
This study provides first clues related to EpCAM and CD44. Our
results demonstrate that these two markers are related to TonEBP
which drives SOX2 expression. Although enhanced drug efflux has
been extensively characterized in chemoresistance, the role of DNA
repair in HCC has not been clearly defined. Here we uncover that var-
ious DNA crosslinks activates the ATM-NF-kB-SOX2 pathway in a
manner dependent on TonEBP and ERCC1/XPF. It appears that the
process of repairing the DNA crosslinks is required for the activation
of ATM.
The data presented here revealed underlying mechanism in HCC
and suggest that targeting TonEBP is an attractive strategy to prevent
recurrence of HCC and sensitizing HCC to chemotherapy. The recruit-
ment of ERCC1/XPF to the chromatin by TonEBP involves protein-
protein interaction between TonEBP and XPF. Breaking up this inter-
action might sensitize HCC cells to chemotherapy as well as blocking
self-renewal of LCSCs.Funding sources
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